494 related articles for article (PubMed ID: 23720945)
1. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
6. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Muñoz-Culla M; Irizar H; Castillo-Triviño T; Sáenz-Cuesta M; Sepúlveda L; Lopetegi I; López de Munain A; Olascoaga J; Baranzini SE; Otaegui D
Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy and natalizumab.
Hellwig K; Gold R
J Neurol; 2011 Nov; 258(11):1920-8. PubMed ID: 21647730
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
Rispens T; Vennegoor A; Wolbink GJ; Polman CH; Killestein J
Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
[TBL] [Abstract][Full Text] [Related]
9. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
10. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
Tur C; Tintoré M; Vidal-Jordana A; Castilló J; Galán I; Río J; Arrambide G; Comabella M; Arévalo MJ; Horno R; Vicente MJ; Caminero A; Nos C; Sastre-Garriga J; Montalban X
Mult Scler; 2012 Aug; 18(8):1193-6. PubMed ID: 22383232
[TBL] [Abstract][Full Text] [Related]
11. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab in relapsing-remitting multiple sclerosis.
Outteryck O
Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
[TBL] [Abstract][Full Text] [Related]
13. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Walker A; Watson C; Alexopoulos ST; Deniz B; Arnold R; Bates D
Curr Med Res Opin; 2014 Apr; 30(4):629-35. PubMed ID: 24289170
[TBL] [Abstract][Full Text] [Related]
14. Deaths and disability from natalizumab are no longer tolerable: Yes.
Duquette P
Mult Scler; 2012 Aug; 18(8):1068-9. PubMed ID: 22807470
[No Abstract] [Full Text] [Related]
15. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
16. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
Sørensen PS
Mult Scler; 2012 Aug; 18(8):1070-2. PubMed ID: 22807471
[No Abstract] [Full Text] [Related]
17. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
Havla J; Berthele A; Kümpfel T; Krumbholz M; Jochim A; Kronsbein H; Ryschkewitsch C; Jensen P; Lippmann K; Hemmer B; Major E; Hohlfeld R
Mult Scler; 2013 Aug; 19(9):1213-5. PubMed ID: 23124790
[TBL] [Abstract][Full Text] [Related]
18. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
Ropper AH
N Engl J Med; 2012 May; 366(20):1938-9. PubMed ID: 22591300
[No Abstract] [Full Text] [Related]
19. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
[TBL] [Abstract][Full Text] [Related]
20. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]